McKesson Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +35

McKesson (MCK) Earns 1.12% on Sales and Has No Equity Left. How Does That Work?

Earnings report AI-generated analysis

πŸ“‰ McKesson reported a sharp 21.70% decline in net earnings while revenue grew 7.70%, driven by a contraction in the operating spread per package.

πŸ’° The company generated $4.59 billion in profit on $410.98 billion in revenue, resulting in a net margin of just 1.12%.

🏦 McKesson holds $6.8 billion in cash against $6.85 billion in operating expenses, effectively retiring its equity and leaving a negative book value per share of $36.55.

πŸ›‘οΈ The company maintains a dominant market position with three firms controlling most US drug distribution, creating a high barrier to entry for new competitors.

πŸ“ˆ The stock traded near $916 on October 5, up 21.72% over the last twelve months, despite recent earnings misses.

πŸ“Š McKesson's operating margin of 1.35% leaves very little buffer above the net margin, making the business highly sensitive to spread changes.

πŸ›οΈ Hedge fund ownership increased slightly in Q2 2026, with 77 funds holding a combined stake value of $4.33 billion.

Bullish Signals
  • McKesson operates an asset-light distribution model that has allowed it to retire its equity entirely, resulting in a negative book value per share while maintaining a massive market presence.
  • The company possesses a durable economic moat as one of only three firms capable of building the necessary national warehouse and approval network for drug distribution.
  • McKesson holds $6.8 billion in cash against $6.85 billion in operating expenses, demonstrating strong liquidity and an ability to fund buybacks without capital spending gaps.
  • The stock has gained 21.72% over the last twelve months, trading at a forward P/E of 19.72x which reflects market confidence in its long-term cash flow generation.
Risk Factors
  • Net earnings fell 21.70% while revenue grew 7.70%, indicating that the company's thin margins are highly vulnerable to minor shifts in pricing spreads.
  • The business operates with a net margin of only 1.12%, meaning a few basis points of spread movement can significantly impact annual profitability.
Full Analysis
McKesson Corporation (NYSE: MCK) reported a significant divergence between top-line growth and profitability in the most recent quarter, with revenue rising 7.70% to $410.98 billion while net earnings fell 21.70% to $4.59 billion. This decline in profit occurred despite the company maintaining its massive distribution network, highlighting the extreme sensitivity of McKesson's thin margins to minor fluctuations in pricing spreads. The company operates with a net margin of just 1.12%, earning approximately one cent for every dollar of sales processed through its national drug distribution system. This asset-light model has allowed McKesson to retire its equity entirely, resulting in a negative book value per share of $36.55, yet the market values the company at $94.37 billion based on its dominant market position and lack of viable competitors. McKesson's financial structure includes $6.8 billion in cash against $6.85 billion in operating expenses, leaving no capital spending gap, while debt stands at $11.8 billion. The stock trades at a price-to-sales ratio of 0.26 and a forward P/E of 19.72x, reflecting investor confidence in the durability of its economic moat despite the lack of equity buffer to absorb earnings volatility.